Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 1.00 |
| ▸ | ATRIP | Q8WXE1 | 20/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.75 |
| ▸ | MTOR | P42345 | 1/20 | 0.75 |
| ▸ | PRKDC | P78527 | 1/20 | 0.75 |
| ▸ | ATM | Q13315 | 1/20 | 0.75 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17527654 | 1.00 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL17501562 | 0.92 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL17501039 | 0.88 | ATR (0.79) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL18110016 | 0.87 | ATR (1.00) | ATRATRIP | |
| SCHEMBL18110015 | 0.87 | ATR (1.00) | ATRATRIP | |
| SCHEMBL22766965 | 0.86 | ATR (1.00) | ATRATRIP | |
| Elimusertib SCHEMBL25080815 | 0.86 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| Elimusertib SCHEMBL17501318 | 0.86 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| Elimusertib SCHEMBL20081876 | 0.86 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| Elimusertib SCHEMBL31602087 | 0.86 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ATR 3508/4885ATRIP 1927/4885GAK 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.